Analysts Offer Predictions for MRKR FY2024 Earnings

Marker Therapeutics, Inc. (NASDAQ:MRKR) – Analysts at Brookline Capital Management issued their FY2024 EPS estimates for Marker Therapeutics in a research note issued to investors on Monday, February 10th. Brookline Capital Management analyst L. Cann expects that the company will post earnings of ($0.25) per share for the year. Brookline Capital Management has a “Strong-Buy” rating on the stock. The consensus estimate for Marker Therapeutics’ current full-year earnings is ($1.05) per share.

Separately, LADENBURG THALM/SH SH raised their target price on shares of Marker Therapeutics from $11.00 to $19.00 and gave the company a “buy” rating in a research note on Monday, October 21st.

Marker Therapeutics Price Performance

MRKR stock opened at $1.70 on Thursday. The firm has a 50 day moving average of $2.84 and a two-hundred day moving average of $3.23. Marker Therapeutics has a 12 month low of $1.48 and a 12 month high of $5.99.

Hedge Funds Weigh In On Marker Therapeutics

A number of institutional investors have recently modified their holdings of the stock. Invst LLC acquired a new stake in shares of Marker Therapeutics during the 3rd quarter worth approximately $56,000. LPL Financial LLC acquired a new position in Marker Therapeutics during the fourth quarter valued at approximately $248,000. Finally, Aisling Capital Management LP grew its holdings in Marker Therapeutics by 3.5% during the fourth quarter. Aisling Capital Management LP now owns 325,370 shares of the company’s stock valued at $1,012,000 after purchasing an additional 11,084 shares during the period. 22.39% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Marker Therapeutics news, Director Steve Elms acquired 11,085 shares of Marker Therapeutics stock in a transaction dated Monday, December 23rd. The stock was bought at an average cost of $3.20 per share, with a total value of $35,472.00. Following the acquisition, the director now owns 325,370 shares of the company’s stock, valued at approximately $1,041,184. The trade was a 3.53 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Enterprise Associates 16 New purchased 554,250 shares of the business’s stock in a transaction that occurred on Monday, December 23rd. The shares were purchased at an average cost of $3.20 per share, with a total value of $1,773,600.00. Following the completion of the acquisition, the insider now directly owns 1,625,678 shares in the company, valued at $5,202,169.60. The trade was a 51.73 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 17.35% of the company’s stock.

About Marker Therapeutics

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.